Clinical trial · Interventional
Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma
Phase II Study of Irinotecan (CPT-11) in Children and Adolescents With High Risk Ewing's Sarcoma
NCT00276692CI-TRIAL-00011077completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well irinotecan works in treating patients with newly diagnosed Ewing's sarcoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| irinotecan hydrochloride | Drug | Irinotecan | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response as measured by MRI following course 2
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 19 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed Ewing's tumor * Ewing's sarcoma or peripheral primitive neuroectodermal tumor of bone or soft tissue * High-risk disease (R3), defined as metastases at extrapulmonary/pleural sites * Newly diagnosed disease * Measurable primary and/or metastatic disease * At least one bidimensionally measurable lesion * Concurrent enrollment on EURO-Ewing99 clinical trial required PATIENT CHARACTERISTICS: * No abnormal cardiac function, including any of the following: * Fractional shortening \< 29% * Ejection fraction \< 40% * Glomerular filtration rate ≥ 60mL/min * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study treatment * No prior or current history of chronic diarrhea, bowel obstruction, sub obstruction, Crohn's disease, or ulcerative colitis * No other medical, psychiatric, or social condition incompatible with the study treatment PRIOR CONCURRENT THERAPY: * No prior chemotherapy * No more than 45 days since prior definitive biopsy
References
Publications (0)
Data not yet available
No reference posted for this study.